Making Real World Evidence Less 'Messy' To Help With Drug Pricing

The Medicines Company's inclisirin CV trial is 100-fold cheaper with digitized records, while Lilly is still hunting for a good HBA1C dataset, and Merck worries about "idiosyncratic" data.

FTI real world evidence Panel — Mark Nagy, Eli Lilly; Susan Shiff, Merck; Clive Meanwell, The Medicines Co. • Source: Photo by Brenda Sandburg

How does real world evidence fit into value-based pricing? A panel of pharmaceutical executives shed light on the issue during the FT Pharma Pricing and Value Summit held in New York Sept. 13.

Susan Shiff, senior VP, Center for Observational and Real-World Evidence at Merck & Co. Inc., said the question concerns...